The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients

The recently published ESC/EAS guidelines for the management of dyslipidaemias have lowered the low-density lipoprotein cholesterol (LDL-C) target in the very high risk patients below 55 mg/dL [1.4 mmol/L] [1]. The drug of choice for achieving this target is high-intensity statin to the highest tolerated dose. If the goal is not achieved, the addition of ezetimibe is recommended first, and then the addition of a proprotein convertase subtilisin/kexin type [9] inhibitor (PCSK9i), if LDL-C remains above target.
Source: Atherosclerosis - Category: Cardiology Authors: Tags: Correspondence Source Type: research

Related Links:

We present normally distributed variables using means and standard deviations and non-normally distributed variables using medians along with their ranges. Spearman's correlation coefficients were used to analyse correlations between the CSF's biomarker concentrations, and both unadjusted and Bonferroni adjusted p-values are reported. Orthogonal projection to latent structure discriminant analysis (OPLS-DA) was also used to find differences in terms of CSF metabolites between the relapsing and remitting patients [CIS, RR, PR versus PP, SP patients]. The OPLS-DA algorithm finds the projection direction, score vector, that g...
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
The Pharmacogenomics Journal, Published online: 06 December 2019; doi:10.1038/s41397-019-0136-7Genetic contribution to lipid target achievement with statin therapy: a prospective study
Source: The Pharmacogenomics Journal - Category: Drugs & Pharmacology Authors: Source Type: research
To prevent heart problems later in life, people 45 and younger with higher levels of bad cholesterol might want to change their eating and exercise habits, or even talk to their doctor about medications such as statins, a new study says.
Source: - Health - Category: Consumer Health News Source Type: news
The Pharmacogenomics Journal, Published online: 05 December 2019; doi:10.1038/s41397-019-0125-xStatin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study
Source: The Pharmacogenomics Journal - Category: Drugs & Pharmacology Authors: Source Type: research
We present the case of a 44-year-old physician with familial heterozygous hypercholesterolemia who experienced multiple tendon ruptures during 19 years of statin therapy and no tendon injuries in the 5 years since statins were discontinued. Statins may deleteriously affect tendon extracellular matrix by inhibiting synthesis of matrix metalloproteinases and cell cycle regulatory proteins. Clinicians should be aware of this possible association between statins and tendinopathy.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Case Report Source Type: research
Researchers are using artificial intelligence to measure a common marker of heart disease via lung cancer screenings. The research was presented at the annual meeting of the Radiological Society of North America (RSNA). Low-dose chest CT is approved for lung cancer screening in high-risk people, such as long-time smokers. While these CT scans are intended to diagnose lung cancer, coronary artery calcium, a measure of plaque in the arteries, is also visible on CT. The coronary artery calcium score derived from CT is a well-established measure that helps doctors decide who should get cholesterol-lowering preventive medicatio...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health IVD Source Type: news
High cholesterol is known to be one of the primary risk factors for heart disease, since it can contribute to plaque buildup in the arteries. But even though the U.S. Centers for Disease Control and Prevention recommends regular cholesterol testing starting around age 20, many Americans don’t give cholesterol—or heart disease, for that matter—much thought until later in life. A new modeling study published in the Lancet gives extra reason not to put off cholesterol screening and treatment. It confirms that high blood levels of “bad” (or non-HDL) cholesterol are associated with a greater risk o...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Research Source Type: news
Understanding risks early on could help protect from disease later in life and ‘offer chance to take statins or adjust diet’All adults as young as 25, as well as older people, need to know of their “bad cholesterol” levels so they can change their lifestyle or take drugs to protect themselves against heart attacks or strokes in later life, say scientists.A landmark study involving data from nearly 400,000 people in 19 countries has established for the first time that levels of non-HDL, or “bad cholesterol”, in the blood are closely linked to the risk of heart disease across the entire li...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: UK news Health Heart attack Stroke Young people Older people Nutrition Science Obesity World news Source Type: news
Young doctors also prescribing to friends and family Related items fromOnMedica GPs need more time to treat complex needs GPs defend practice on prescribing statins Double check patients with ‘penicillin’ allergy to avoid MRSA risk Clinicians need better options if we are to stop over-medication MHRA tightens licence restrictions on valproate for women
Source: OnMedica Latest News - Category: UK Health Source Type: news
ConclusionsOur findings showed that a large proportion of patients with SLE have a considerable cardiovascular risk and many of them would be eligible for statin therapy. However, the statin use observed was low.Key Points• A large proportion of patients with lupus have a considerable cardiovascular risk, explained in part by dyslipidemia.• Many patients with SLE would be eligible for statin therapy according to risk stratification based on conventional risk factors.• The use of statins in this population is inadequate.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
More News: Cardiology | Cholesterol | Statin Therapy | Vytorin | Zetia